Table 3.
Univariate and Adjusted Hazard Ratios
| Patients | AC v AT
|
||
|---|---|---|---|
| HR* | 95% CI | P | |
| Eligible (n = 2,882) | |||
| DFS | 1.02 | 0.86 to 1.22 | .78 |
| DFS adjusted† | 1.03 | 0.87 to 1.22 | .74 |
| OS | 1.06 | 0.85 to 1.31 | .62 |
| OS adjusted† | 1.06 | 0.85 to 1.31 | .63 |
| All (N = 2,952) | |||
| DFS | 1.02 | 0.86 to 1.21 | .83 |
| DFS adjusted† | 1.03 | 0.87 to 1.22 | .76 |
| OS | 1.03 | 0.83 to 1.28 | .76 |
| OS adjusted† | 1.04 | 0.84 to 1.30 | .73 |
Abbreviations: AC, doxorubicin and cyclophosphamide; AT, doxorubicin and docetaxel; HR, hazard ratio; DFS, disease-free survival; OS, overall survival.
*
HR > 1 indicates improved outcome for AT.
†
Adjusted for age, menopausal status, primary surgery, estrogen receptor/progesterone receptor status, nodal status, tumor size, and tumor grade.